Investor Relations

Press Releases

08 Aug 22

Prenetics Launches Circle Snapshot, Simple At-home Blood Tests Using the World’s First Push-Button and Painless Blood Collection Device

Circle Snapshot, a patented, painless, at-home blood test with laboratory results delivered digitally. The test utilises a CE-certified blood collection device, which is a proprietary micro-needle technology that draws capillary blood painlessly using a novel microfluidic extraction process.

08 Jun 22

Prenetics Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong Kong

Highly sensitive ColoClear test offers convenient screening method that can be completed with simple stool sample at-home, providing an easy alternative to Colonoscopy Test sensitivity of 96% in colorectal cancer and 64% in advanced adenoma detection in clinical studies ColoClear is the only cancer

06 Jun 22

Prenetics Announces First Quarter 2022 Financial Results After a Successful Listing on the Nasdaq under the Ticker “PRE”

LONDON and HONG KONG, June 06, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the first quarter ended March 31, 2022.

23 May 22

New Horizon Health Partners with Prenetics in Hong Kong to Launch ColoClear, a Non-Invasive Stool DNA Test to Detect Colon Cancer

(Hangzhou & Hong Kong, 23 May 2022) New Horizon Health (6606.HK) and Prenetics Group Limited (Nasdaq: PRE, “Prenetics”) has announced a strategic partnership to launch ColoClear by Circle (ColoClear), the “First Colorectal Cancer Screening Test approved in China”, in Hong Kong, and for its first

View All News

Key Financials –
FY2021 Earnings

Stock Information

Press Releases

Recent Events

Featured Reports

INVESTOR RELATIONS

Key Financials – FY2021 Earnings

Stock Information

Press Releases

Recent Events

Featured Reports

Key Financials –
FY2021 Earnings